… Pipeline Drugs Emerging drugs use a number of new and traditional mechanisms to reduce
IOP. The drugs discussed in our review are in development and range from preclinical trials …

… The ocular hypertension (OHT) and the deleterious mechanical forces it exerts at the
back of the eye, at the level of the optic nerve head/optic disc and lamina cribosa, is the only …

… Despite numerous surgical approaches and classes of IOP-lowering drugs available,
glaucoma remains a challenging chronic disease. Many new emerging strategies including …

… drugs or drug targets for treating glaucoma is a hot emerging … Ripasudil to treat glaucoma
and ocular hypertension. This led to … , the US FDA approved ocular netarsudil (Rhopressa ® ) …

… In this review, we identify synthetic ocular hypotensive drugs in the early stages of
development. We do not discuss directly formulations that aim to reduce risk for glaucoma …

… ocular hypertension and open-angle glaucoma in the Laser in Glaucoma and Ocular
Hypertension (… In addition, a large majority of patients in that study had ocular hypertension or mild …

… ocular hypotensive agents since the US Food and Drug … with glaucoma and ocular
hypertension represents a triumph in … combined with other known ocular hypotensive medications. …

… ,226] to permit screening of potential ocular hypotensive drug candidates. While translation
of … of new clinically viable drugs with high enough therapeutic indices have emerged to which …

… in pseudophakic eye without history of ocular hypertension. The FAME trials showed its efficacy
… drugs have demonstrated efficacy and safety but a significant rate of ocular hypertension …

… Rho kinase is an enzyme that increases filament contractions in ocular muscle cells. Thus,
enzyme inhibition with drug therapy relaxes trabecular smooth muscles, improves aqueous …